News

DiaGen Ai Inc. Announces Partnership with Cambridge, UK Based The Vaccine Group LTD. to Co-Develop Novel Vaccines

DiaGen Ai Inc. Announces Partnership with Cambridge, UK Based The Vaccine Group LTD. to Co-Develop Novel Vaccines

DiaGen Ai Inc. is pleased to announce its partnership with The Vaccine Group LTD., based in Cambridge, UK, to develop novel vaccines for the veterinary market using DiaGen’s AI engine. This collaboration aims to optimize protein structures and advance TVG’s vaccine pipeline. TVG’s CEO, Jeremy Salt, highlighted the complementary AI approaches, while DiaGen’s President, Paolo Lobo, expressed excitement about entering the Veterinary sector.

read more
DiaGen Ai Inc., Announces Unit Financing and Appointment of Davidson & Company, LLP as Independent Auditor

DiaGen Ai Inc., Announces Unit Financing and Appointment of Davidson & Company, LLP as Independent Auditor

VANCOUVER, BC, CANADA, March 6, 2024 /EINPresswire.com/ — DiaGen AI Inc. announces a successful first closing of its non-brokered unit financing, raising $198,195. Each unit, priced at $0.135, includes one common share and one-half of a common share purchase warrant with an exercise price of $0.20. The financing aims to advance DiaGen’s proprietary AI engine, innovate peptides, and molecules, while scaling partnerships in health and wellness.

Highlights:

Successful First Tranche: Raised $198,195, issuing 1,468,116 common shares and 734,058 warrants.

Canaccord Genuity Corp. as finder.

read more
Proteic Biosciences Inc. Announces Name Change to DiaGen Ai Inc., the Appointment of a New CEO, New Website and Update

Proteic Biosciences Inc. Announces Name Change to DiaGen Ai Inc., the Appointment of a New CEO, New Website and Update

VANCOUVER, BC, CANADA, December 13, 2023 /EINPresswire.com/ — Proteic Biosciences Inc., now DiaGen AI Inc., pioneers in AI-driven protein design and drug discovery, reveals its corporate rebrand. Alongside, Brian D. Keane, former Proteic capital markets advisor, assumes the role of CEO and Chairman, bringing 30 years of legal and capital markets expertise.

Paolo Lobo, President of DiaGen AI, emphasizes, “Our rebrand showcases our focus as an AI company advancing healthcare through protein design and innovation.”

read more